Both the novel MAPK and MEK 1/2 drugs can cause serious ocular toxicities, including retinal vein occlusion, uveitis, and retinal pigment epithelial detachment, which limit their use in the current state [22]. This evidence concerns the gene MAP2K1 and retinal vein occlusion.